SCHEMBL30206285

SCHEMBL30206285

CNc1nc(F)c(C(=O)OC)nc1Cl

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.44
▸ PGK1 P00558 1/20 0.39
▸ KDM4E B2RXH2 7/20 0.35
▸ ALDH1A1 P00352 7/20 0.35
▸ SMN1; SMN2 Q16637 5/20 0.35
▸ PKM P14618 3/20 0.35
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ RCE1 Q9Y256 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.32
▸ PLAU P00749 1/20 0.32
▸ HPGD P15428 1/20 0.31
▸ KDM4C Q9H3R0 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173359 1.00 NPSR1 (0.44) NPSR1PGK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL12389585 0.81 PLAU (0.46) NPSR1PGK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL30205978 0.81 PLAU (0.46) NPSR1PGK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL29173419 0.80 NPSR1 (0.44) NPSR1PGK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL11727826 0.80 NPSR1 (0.44) NPSR1PGK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL30206204 0.79 NPSR1 (0.47) NPSR1KDM4EALDH1A1SMN1; SMN2PKM
SCHEMBL29173440 0.79 NPSR1 (0.47) NPSR1KDM4EALDH1A1SMN1; SMN2PKM
SCHEMBL29173541 0.78 NPSR1 (0.45) NPSR1KDM4EALDH1A1SMN1; SMN2PKM
SCHEMBL30205955 0.78 NPSR1 (0.45) NPSR1KDM4EALDH1A1SMN1; SMN2PKM
SCHEMBL30206069 0.77 NPSR1 (0.44) NPSR1KDM4EALDH1A1SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback